An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. (Q37049990)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Carle Paul

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Richard G B Langley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Thomas A Luger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Dirk Schneider

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

18 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

215 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

27-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

Quality of life in atopic dermatitis.

31 December 2019

cites work

1 reference

Topical corticosteroid phobia in patients with atopic eczema

21 January 2018

1 reference

Optimal management of atopic dermatitis

21 January 2018

1 reference

Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence

21 January 2018

1 reference

Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions

21 January 2018

1 reference

Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis

21 January 2018

1 reference

Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis

21 January 2018

1 reference

Pimecrolimus for the treatment of inflammatory skin disease

21 January 2018

1 reference

Pimecrolimus -- an anti-inflammatory drug targeting the skin

21 January 2018

1 reference

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus

21 January 2018

1 reference

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

21 January 2018

1 reference

Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years

21 January 2018

1 reference

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

21 January 2018

1 reference

First experience of topical SDZ ASM 981 in children with atopic dermatitis

21 January 2018

1 reference

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

21 January 2018

1 reference

Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.

21 January 2018

1 reference

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

21 January 2018

1 reference

Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin

21 January 2018

1 reference

Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.

21 January 2018

1 reference

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies

21 January 2018

1 reference

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

21 January 2018

1 reference

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

21 January 2018

1 reference

Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis

21 January 2018

1 reference

Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.

21 January 2018

1 reference

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

21 January 2018

1 reference

A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis

21 January 2018

1 reference

Management of opportunistic infections in solid-organ transplantation

21 January 2018

1 reference

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin

21 January 2018

1 reference

Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities

21 January 2018

1 reference

Incidence of skin cancer in 5356 patients following organ transplantation

21 January 2018

1 reference

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

21 January 2018

1 reference

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

21 January 2018

1 reference

Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis

21 January 2018

1 reference

Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000102118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18174691%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference